A not so easy genotype—striking regional differences in SOF SOF / RBV RBV treatment responses in HCV GT HCV GT 2

Tacke Frank; Mauss Stefan

首页> 外文期刊>Liver international : >A not so easy genotype—striking regional differences in SOF SOF / RBV RBV treatment responses in HCV GT HCV GT 2

【24h】

A not so easy genotype—striking regional differences in SOF SOF / RBV RBV treatment responses in HCV GT HCV GT 2

机译：SOF SOF / RBV RBV治疗反应在HCV GT HCV GT 2中不那么简单的基因型引起的区域差异

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Liver international :》 |2017年第8期|共2页
作者
Tacke Frank; Mauss Stefan;
展开▼
作者单位

Department of Medicine IIIUniversity Hospital AachenAachen Germany;

Center for HIV and HepatogastroenterologyDuesseldorf Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
中文文献
专利

1. A not so easy genotype—striking regional differences in SOF SOF / RBV RBV treatment responses in HCV GT HCV GT 2 [J] . Tacke Frank, Mauss Stefan Liver international : . 2017,第8期

机译：SOF SOF / RBV RBV治疗反应在HCV GT HCV GT 2中不那么简单的基因型引起的区域差异
2. Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection [J] . Asselah Tarik, Shiha Gamal, Feld Jordan J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：用于治疗基因型4慢性HCV感染的SOF Plus RBV，LDV / SOF或SOF / Vel的综合分析
3. Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD) [J] . Bourliere Marc, Charlton Michael R., Manns Michael P., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：使用ledipasvir / sofosbuvir（LDV / SOF）与基因型1（GT 1）HCV感染患者的基因型（GT 1）HCV感染患者（LT）：评估几个现实世界数据集（RWD）
4. Safety of Peginterferon alfa-2a (PEGASYS) 180 mcg Weekly Plus Ribavirin (RBV) 800 mg Daily in HIV/HCV Coinfection Compared to HCV Monoinfection [C] . N. Brau, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：Peginterferon Alfa-2a（Pegasys）的安全性为180 mcg每周加上利韦韦林（RBV）800mg在HIV / HCV辛纤维中每日800毫克，与HCV单键相比
5. Mathematical Modeling as a Tool to Elucidate HCV Infection Kinetics and Treatment Response [D] . Sansone, Natasha D. 2017

机译：数学模型作为阐明HCV感染动力学和治疗反应的工具
6. A168 USE OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) WITH OR WITHOUT RIBAVIRIN (RBV) IN GENOTYPE 1 (GT 1) HCV-INFECTED PATIENTS POST LIVER TRANSPLANT (LT): EVALUATION OF SEVERAL REAL-WORLD DATASETS (RWD) [O] . M Bourliere, M Charlton, M Manns, 2018

机译：A168在肝移植后（LT）的基因型1（GT 1）HCV感染患者中使用带或不带利巴韦林（RBV）的LEDIPASVIR / SOFOSBUVIR（LDV / SOF）：评估多个真实世界数据集（RWD）
7. Efficacy of a 12-week simeprevir plus peginterferon/ribavirin (PR) regimen in treatment-naïve patients with Hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment virologic response [O] . Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, 2017

机译：一项12周的Simeprevir加聚乙二醇干扰素/利巴韦林（PR）方案对未接受治疗的C型肝炎病毒（HCV）基因型4（GT4）感染和轻中度纤维化的患者显示早期治疗病毒学应答的疗效

A not so easy genotype—striking regional differences in SOF SOF / RBV RBV treatment responses in HCV GT HCV GT 2

著录项

相似文献

相关主题

期刊订阅